Stay updated with breaking news from Leukodystrophy Service. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis
/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced...
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease - read this article along with other careers information, tips and advice on BioSpace
Message : Required fields First Data Presented Showcasing Autobahn’s Novel FAAH-Mediated Prodrug Approach for Selective Delivery of Thyromimetics to the Brain Treatment with ABX-002 Leads to Reductions in VLCFA in Brain Tissue and Plasma in AMN Mouse Model Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the presentation of preclinical data of ABX-002, a CNS-penetrating prodrug that provides a balanced delivery of LL-340001, a potent and selective thyroid hormone receptor beta (TRβ) agonist, for the potential t...
Share: First Data Presented Showcasing Autobahn's Novel FAAH-Mediated Prodrug Approach for Selective Delivery of Thyromimetics to the Brain Treatment with ABX-002 Leads to Reductions in VLCFA in Brain Tissue and Plasma in AMN Mouse Model Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the presentation of preclinical data of ABX-002, a CNS-penetrating prodrug that provides a balanced delivery of LL-340001, a potent and selective thyroid hormone receptor beta (TRβ) agonist, for the potential treatment of adrenomye...